Celgene International Sárl (CELG) Release: Phase II Study Evaluating Apremilast as an Oral Treatment for Patients with Ankylosing Spondylitis Presented at Celgene International Sárl (CELG)

11/8/2011 8:41:26 AM

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), today announced data from a Phase II study of apremilast, its investigational oral immunomodulatory compound, in patients with ankylosing spondylitis (AS) were presented at the American College of Rheumatology Scientific Meeting in Chicago, IL. Based on the data from this study, the company will be initiating a Phase III placebo-controlled trial with apremilast in ankylosing spondylitis during the first half of 2012.

Read at BioSpace.com

Read Article at

Related Companies

News Categories

• BioSpace.com

• Celgene International Sárl

• Clinical - Phase II

• Biotech/Pharma - Events

• Biotech/Pharma - Events (World)

• Clinical - Phase II (World)